JAMA Pub Date : 2025-07-24 DOI: 10.1001/jama.2025.10585

Roy Perlis,Jessica Watts

引用次数: 0

Acute Respiratory Distress Syndrome and Inhaled Sedation. 急性呼吸窘迫综合征和吸入镇静。

JAMA Pub Date : 2025-07-23 DOI: 10.1001/jama.2025.8698

Claudia Vera-Ching,Francisco Jose Parrilla-Gómez

引用次数: 0

Acute Respiratory Distress Syndrome and Inhaled Sedation-Reply. 急性呼吸窘迫综合征与吸入镇静反应。

JAMA Pub Date : 2025-07-23 DOI: 10.1001/jama.2025.8701

Matthieu Jabaudon,Emmanuel Futier,Jean-Michel Constantin

引用次数: 0

Poetry and the Will to Survive-Or Simply to Write. 诗歌与生存意志——或仅仅是写作意志。

JAMA Pub Date : 2025-07-23 DOI: 10.1001/jama.2025.5810

Rafael Campo

引用次数: 0

Sequelae and Care After Firearm Injury. 枪械伤害后的后遗症和护理。

JAMA Pub Date : 2025-07-23 DOI: 10.1001/jama.2025.10498

Bethany L Strong,Margaret H Lauerman,Thomas M Scalea

引用次数: 0

Ovarian Cancer 卵巢癌

JAMA Pub Date : 2025-07-21 DOI: 10.1001/jama.2025.9495

Giuseppe Caruso, S. John Weroha, William Cliby

{"title":"Ovarian Cancer","authors":"Giuseppe Caruso, S. John Weroha, William Cliby","doi":"10.1001/jama.2025.9495","DOIUrl":"https://doi.org/10.1001/jama.2025.9495","url":null,"abstract":"ImportanceOvarian cancer is the eighth most common cause of cancer and cancer death in women worldwide. In 2022, ovarian cancer was diagnosed in approximately 324 398 individuals, and 206 839 died of ovarian cancer worldwide. In 2025, it is estimated that 20 890 US women will be diagnosed with ovarian cancer and 12 730 patients will die of ovarian cancer.ObservationsApproximately 90% of ovarian cancers are epithelial malignancies, of which 70% to 80% are high-grade serous ovarian cancers. Less common epithelial subtypes include endometrioid, clear cell, low-grade serous, mucinous, and carcinosarcoma. The median age at diagnosis of ovarian cancer is 63 years. Risk factors include older age, family history of breast or ovarian cancer, endometriosis, and nulliparity. Hereditary factors are associated with 25% of cases, predominantly linked to <jats:italic>BRCA1</jats:italic>/<jats:italic>2</jats:italic> gene variants. At diagnosis, approximately 95% of patients experience nonspecific symptoms, such as abdominal pain, bloating, and urinary urgency and frequency, and about 80% have advanced-stage disease (stage III-IV), including extrapelvic disease, ascites, and abdominal masses. Diagnostic and staging evaluation includes pelvic ultrasound; computed tomography of the chest, abdomen, and pelvis; and serum tumor markers such as carbohydrate antigen 125, carbohydrate antigen 19-9, and carcinoembryonic antigen. First-line treatment for early-stage ovarian cancer, defined as limited to the ovary or fallopian tube (stage I) or confined to the pelvis (stage II), is surgery (hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy), followed by adjuvant chemotherapy (carboplatin and paclitaxel). With treatment, early-stage ovarian cancer has a 5-year overall survival of 70% to 95%. Advanced-stage ovarian cancer may be treated with primary cytoreductive surgery (removal of all visible cancer in the abdominal cavity) and adjuvant chemotherapy (carboplatin and paclitaxel) or with neoadjuvant chemotherapy followed by cytoreductive surgery and adjuvant chemotherapy. Most patients with advanced-stage ovarian cancer receive maintenance therapy with bevacizumab (a monoclonal antibody that blocks angiogenesis) and/or poly–adenosine diphosphate ribose polymerase (PARP) inhibitors. With treatment, the 5-year overall survival rate for advanced-stage ovarian cancer is 10% to 40%. However, individuals with <jats:italic>BRCA</jats:italic>-related gene variants have a 5-year overall survival rate of approximately 70% with PARP inhibitor treatment. Despite an initial remission rate of 80%, approximately 75% of patients with advanced-stage disease have ovarian cancer relapse within 2 years.Conclusions and RelevanceApproximately 21 000 women are diagnosed with ovarian cancer annually in the US, and approximately 80% have advanced-stage ovarian cancer at diagnosis. First-line treatment of early-stage ovarian cancer is surgery and adjuvant platinum-based c","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"282 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CDC Reports Drop in Fast-Food Intake Among Both Adults and Youth. 美国疾病控制与预防中心报告，成年人和青少年的快餐摄入量都有所下降。

JAMA Pub Date : 2025-07-18 DOI: 10.1001/jama.2025.10331

Samantha Anderer

引用次数: 0

Global Childhood Vaccination Progress Has Stalled in Recent Decades. 近几十年来，全球儿童疫苗接种进展停滞不前。

JAMA Pub Date : 2025-07-18 DOI: 10.1001/jama.2025.10333

Samantha Anderer

引用次数: 0

Once-Weekly Basal Insulin Matches Daily Option in Type 2 Diabetes Trial. 2型糖尿病试验：每周一次基础胰岛素匹配每日选择

JAMA Pub Date : 2025-07-18 DOI: 10.1001/jama.2025.10332

Samantha Anderer